MB, Levis & Associates’s Oracle ORCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$52.5K Buy
358
+1
+0.3% +$181 0.02% 104
2026
Q1
$52.6K Hold
357
0.02% 103
2025
Q4
$69.5K Buy
357
+1
+0.3% +$238 0.03% 95
2025
Q3
$100K Buy
356
+1
+0.3% +$255 0.04% 78
2025
Q2
$77.7K Buy
355
+1
+0.3% +$161 0.03% 103
2025
Q1
$49.5K Hold
354
0.02% 120
2024
Q4
$58.9K Buy
354
+1
+0.3% +$178 0.03% 110
2024
Q3
$60.1K Buy
353
+51
+17% +$7.39K 0.03% 112
2024
Q2
$42.7K Buy
302
+1
+0.3% +$124 0.02% 121
2024
Q1
$37.8K Buy
301
+1
+0.3% +$114 0.02% 126
2023
Q4
$31.6K Hold
300
0.02% 133
2023
Q3
$31.8K Hold
300
0.02% 135
2023
Q2
$35.7K Hold
300
0.02% 137
2023
Q1
$27.9K Hold
300
0.02% 144
2022
Q4
$24.5K Buy
+300
New +$22.8K 0.02% 137

Other funds holding ORCL

MB, Levis & Associates's ORCL Position: Q2 2026 in Review

MB, Levis & Associates increased its Oracle (ORCL) stake by 0.28% in Q2 2026, buying an estimated $181 and bringing the position to 358 shares worth $52.5K. The position accounts for 0.02% of the portfolio, ranked #104.

MB, Levis & Associates first reported a position in ORCL in Q4 2022 and has held it in 15 quarters since. The position peaked at $100K in Q3 2025. 1,577 funds tracked by Wall St. Rank hold ORCL as of Q2 2026.

  • MB, Levis & Associates held 358 shares of Oracle worth $52.5K as of Q2 2026.
  • MB, Levis & Associates bought 1 Oracle share in Q2 2026, an estimated $181.
  • Oracle made up 0.02% of MB, Levis & Associates's portfolio in Q2 2026, its #104 holding.
  • MB, Levis & Associates first reported a position in Oracle in Q4 2022 and has held it in 15 quarters since.
  • MB, Levis & Associates's Oracle position peaked at $100K in Q3 2025.
  • 1,577 funds tracked by Wall St. Rank held Oracle as of Q2 2026.

Based on MB, Levis & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.